Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

• US 10,448,662 B2
• Filed: 10/28/2016
• Issued: 10/22/2019
• Est. Priority Date: 10/29/2015
• Status: Active Grant

• Current Assignee: Industry Academic Cooperation Foundation, Y-Biologic, Inc.
• Original Assignee: Y-Biologic, Inc.
• Inventors: Park, Young Woo, Park, Bum-chan, Cha, Bong-soo, Lee, Yong Ho, Lim, Jung Chae, Cho, Young-gyu, Kim, Joong Kyu, Park, Jae Eun, Yoo, Seok Ho
• Primary Examiner(s): Bunner, Bridget E
• Application Number:
  US15/337,208
• Publication Number:
  US 20170121380A1
• Time in Patent Office: 1,089 Days
• CPC Class Codes: A23L 33/17 Amino acids, peptides or proteins
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 47/68 the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• CPC Class Codes: C07K 14/4713 Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Claims

1. A method for treating an insulin resistance-associated disease in a subject in need of treatment, said method comprising the step of administering a delta-like 1 homolog (DLK1)-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region, wherein the DLK1-Fc fusion protein is composed of the amino acid sequence represented by SEQ ID NO:

4 and wherein the insulin resistance-associated disease is Type 2 diabetes, obesity, hypertension, hypertriglyceridemia, low high density lipoprotein (HDL) cholesterolemia, coronary artery disease, non-alcoholic fatty liver disease (NALDF) or atherosclerosis.